Department of Internal Medicine, Advocate Illinois Masonic Medical Center, 836 W. Wellington Ave, Chicago, IL 60657, USA.
Department of Cardiovascular Diseases, Mayo Clinic, 200 First St, Rochester, MN 55905, USA.
Europace. 2018 Mar 1;20(3):535-540. doi: 10.1093/europace/euw396.
Atrial arrhythmias are common in patients with Ebstein's anomaly (EA) despite cardiac surgical repair and concomitant Maze procedures. We aimed to evaluate the outcome of radiofrequency catheter ablation in this group of patients.
All patients with EA and atrial arrhythmias who underwent catheter ablation for atrial arrhythmias between 1/1999 and 1/2016 were included. Atrial arrhythmia recurrence was identified as the primary outcome; secondary outcomes included repeat ablation, need for antiarrhythmic medications after ablation, and death. Predictors of recurrence were sought using univariate analysis. 22 patients (median age 42 years, 54.5% male) were included. Atrial flutter was the most common presenting arrhythmia (n = 14 patients, 63.5%), whereas focal atrial tachycardia (FAT) and atrial fibrillation were identified in 5 (22.7%) and 2 patients (9.1%), respectively, with both atrial flutter/fibrillation evident in a single patient 1 (4.5%). 8 patients (36.4%) had a history of right-sided maze procedures. Cavotricuspid isthmus atrial flutter (CTI-AFl) was the most commonly induced arrhythmia (n = 13, 59.1%), followed by incisional intra-atrial re-entrant tachycardia (IART; n = 4, 18.2%), and FAT (n = 4, 18.2%); 3 patients also underwent left-side ablation with concomitant pulmonary vein isolation (13.6%). 1-year and 5-year atrial arrhythmia recurrence rates were 10.0% and 41.2%, respectively. 7 patients (31.8%) underwent redo ablations, and anti-arrhythmic medication was utilized in 8 patients (36.4%) post-ablation. Neither ablation location nor echocardiographic parameters were found to be predictors of arrhythmia recurrence.
Catheter ablation of atrial arrhythmias in patients with EA has a favorable outcome overall with an acceptable recurrence and safety profile; left-sided ablations are rarely necessary. Despite prior Maze and catheter ablation procedures, CTI-AFl and IART recurrences predominate.
尽管接受了心脏手术修复和同期迷宫手术,Ebstein 异常(EA)患者仍常发生房性心律失常。我们旨在评估该组患者射频导管消融的结果。
纳入了 1999 年 1 月至 2016 年 1 月间因房性心律失常而行导管消融术的所有 EA 合并房性心律失常患者。房性心律失常复发是主要结局;次要结局包括再次消融、消融后抗心律失常药物的需要以及死亡。使用单因素分析寻找复发的预测因素。共纳入 22 例患者(中位年龄 42 岁,54.5%为男性)。最常见的表现性心律失常为房扑(n=14 例,63.5%),5 例(22.7%)为局灶性房性心动过速(FAT),2 例(9.1%)为心房颤动,单一患者(4.5%)同时存在房扑和心房颤动。8 例(36.4%)有右侧迷宫手术史。三尖瓣峡部房扑(CTI-AFl)是最常诱发的心律失常(n=13,59.1%),其次是心内切口折返性房性心动过速(IART;n=4,18.2%)和 FAT(n=4,18.2%);3 例患者还接受了左侧消融术,同时行肺静脉隔离(13.6%)。1 年和 5 年的房性心律失常复发率分别为 10.0%和 41.2%。7 例(31.8%)患者行再次消融,8 例(36.4%)患者消融后使用抗心律失常药物。消融部位和超声心动图参数均不是心律失常复发的预测因素。
EA 患者的房性心律失常导管消融总体上有良好的效果,复发率和安全性可接受;很少需要进行左侧消融。尽管进行了既往的迷宫和导管消融术,CTI-AFl 和 IART 仍会复发。